We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 1,546

The safe harbor for FDA submissions expands: did the Federal Circuit reverse course?

  • Jones Day
  • -
  • USA
  • -
  • August 29 2012

Section 271(e)(1) of the patent code, known as the "safe harbor" provision, immunizes from infringement suits various acts that are undertaken in order to submit information to the Food and Drug Administration ("FDA"

FTC announces revised thresholds for HSR premerger filings and interlocking directorates

  • Jones Day
  • -
  • USA
  • -
  • January 9 2009

On January 7, 2009 the Federal Trade Commission announced revised thresholds for Hart-Scott-Rodino ("HSR") Premerger Notification filings and for the jurisdictional thresholds that trigger the prohibition on interlocking directorates under Section 8 of the Clayton Act

Supreme Court rules that employee may bring Title VII retaliation claim based upon discrimination charge filed by co-employee

  • Jones Day
  • -
  • USA
  • -
  • January 31 2011

On January 24, 2011, the Supreme Court held unanimously that an employee could bring a claim of retaliation against his former employer under Title VII of the Civil Rights Act of 1964 ("Title VII"), even though the employee did not himself file the charge of discrimination that triggered the alleged retaliation

Second Circuit settles the meaning of settlement payments under section 546(e) of the Bankruptcy Code

  • Jones Day
  • -
  • USA
  • -
  • December 6 2011

The powers and protections granted to a bankruptcy trustee or chapter 11 debtor in possession under the Bankruptcy Code are numerous and far-reaching

California begins distribution and auction of "cap and trade" emission allowances

  • Jones Day
  • -
  • USA
  • -
  • November 13 2012

California has begun the process of distributing and auctioning greenhouse gas emission allowances under its "cap and trade" program

Fed clarifies implementation date for Volcker Rule (April 19, 2012)

  • Jones Day
  • -
  • USA
  • -
  • April 27 2012

The Board of Governors of the Federal Reserve System (the “Fed”) announced its approval of a statement clarifying that an entity covered by Section 619 of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Volcker Rule”) has the full two-year period provided by the statute to fully conform its activities and investments, unless the Fed further extends the conformance period

Oversecured creditor entitled to default interest if collateral sold under Section 363(b)

  • Jones Day
  • -
  • USA
  • -
  • October 22 2008

An oversecured creditor's right to interest, fees, and related charges as part of its allowed secured claim in a bankruptcy case is well established in U.S bankruptcy law

U.S. DOJ files antitrust challenge to consummated transaction

  • Jones Day
  • -
  • USA
  • -
  • December 29 2008

In another reminder that U.S. antitrust enforcers can challenge mergers even after closing, and even for deals not subject to premerger notification under the HSR Act, on December 18, 2008, the Department of Justice Antitrust Division filed a civil antitrust lawsuit challenging the July 2008 acquisition by Microsemi Corporation of Semicoa Inc

Publicprivate initiative formed to prevent health care fraud

  • Jones Day
  • -
  • USA
  • -
  • December 6 2012

On July 26, 2012, HHS and DOJ announced a new collaborative arrangement among the federal government, state officials, private health insurance organizations, and other anti-fraud groups to combat and prevent health care fraud

FTC "no action" on pharmaceutical patent settlements does not spell end to reverse payments dispute

  • Jones Day
  • -
  • USA
  • -
  • March 31 2009

Earlier this month, Federal Trade Commission staff sent letters to four pharmaceutical companies disclosing its current intention not to challenge pharmaceutical litigation settlement agreements